196 related articles for article (PubMed ID: 15024534)
1. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions.
Lee AY; Kim MJ; Chey WY; Choi J; Kim BG
Eur J Clin Pharmacol; 2004 May; 60(3):155-9. PubMed ID: 15024534
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
[TBL] [Abstract][Full Text] [Related]
3. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
Twardowschy CA; Werneck LC; Scola RH; De Paola L; Silvado CE
Arq Neuropsiquiatr; 2011 Apr; 69(2A):153-8. PubMed ID: 21537551
[TBL] [Abstract][Full Text] [Related]
4. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Chang WC; Hung SI; Carleton BC; Chung WH
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
[TBL] [Abstract][Full Text] [Related]
5. Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India.
Ramasamy K; Narayan SK; Chanolean S; Chandrasekaran A
Neurol India; 2007; 55(4):408-9. PubMed ID: 18040121
[TBL] [Abstract][Full Text] [Related]
6. Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
Fohner AE; Rettie AE; Thai KK; Ranatunga DK; Lawson BL; Liu VX; Schaefer CA
Clin Transl Sci; 2020 Sep; 13(5):1004-1009. PubMed ID: 32216088
[TBL] [Abstract][Full Text] [Related]
7. The association between CYP 2C9 polymorphism and bone health.
Phabphal K; Geater A; Limapichat K; Sathirapanya P; Setthawatcharawanich S; Leelawattana R
Seizure; 2013 Nov; 22(9):766-71. PubMed ID: 23849849
[TBL] [Abstract][Full Text] [Related]
8. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
9. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
[TBL] [Abstract][Full Text] [Related]
10. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
11. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.
Suvichapanich S; Jittikoon J; Wichukchinda N; Kamchaisatian W; Visudtibhan A; Benjapopitak S; Nakornchai S; Manuyakorn W; Mahasirimongkol S
J Hum Genet; 2015 Aug; 60(8):413-7. PubMed ID: 25994870
[TBL] [Abstract][Full Text] [Related]
12. The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions.
Hassoun-Kheir N; Bergman R; Weltfriend S
Int J Dermatol; 2016 Nov; 55(11):1219-1224. PubMed ID: 27368159
[TBL] [Abstract][Full Text] [Related]
13. Association of
John S; Balakrishnan K; Sukasem C; Anand TCV; Canyuk B; Pattharachayakul S
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442381
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.
Schwarz UI
Eur J Clin Invest; 2003 Nov; 33 Suppl 2():23-30. PubMed ID: 14641553
[TBL] [Abstract][Full Text] [Related]
15. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.
Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
Biochem Biophys Res Commun; 2002 Nov; 299(1):25-8. PubMed ID: 12435384
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258
[TBL] [Abstract][Full Text] [Related]
17. Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients.
Phabphal K; Geater A; Limapichart K; Sathirapanya P; Setthawatcharawanich S
Seizure; 2013 Mar; 22(2):103-8. PubMed ID: 23159358
[TBL] [Abstract][Full Text] [Related]
18. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects.
Soga Y; Nishimura F; Ohtsuka Y; Araki H; Iwamoto Y; Naruishi H; Shiomi N; Kobayashi Y; Takashiba S; Shimizu K; Gomita Y; Oka E
Life Sci; 2004 Jan; 74(7):827-34. PubMed ID: 14659971
[TBL] [Abstract][Full Text] [Related]
19. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption.
Kim SH; Kim SH; Yoon HJ; Shin DH; Park SS; Kim YS; Park JS; Jee YK
Eur J Clin Pharmacol; 2011 Feb; 67(2):121-7. PubMed ID: 20941486
[TBL] [Abstract][Full Text] [Related]
20. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM
Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
